Vascular endothelial growth factor a competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses

Molecular and Cellular Biology

Volumn 32, Issue 10, 2012, Pages 1955-1966

  Pennock, Steven ^a   Kazlauskas, Andrius ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DIMERIZATION; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; VITREORETINOPATHY; VITREOUS BODY;

BINDING, COMPETITIVE; CELL LINE; HUMANS; PLATELET-DERIVED GROWTH FACTOR; PROTEIN BINDING; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECOMBINANT PROTEINS; RETINAL PIGMENT EPITHELIUM; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREORETINOPATHY, PROLIFERATIVE;

ANIMALIA;

EID: 84861385990     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.06668-11     Document Type: Article

References (62)

1. Aiello LP, et al. 1995. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. U. S. A. 92: 10457-10461.
2. Ak P, Levine AJ. 2010. p53 and NF-κB: different strategies for responding to stress lead to a functional antagonism. FASEB J. 24:3643-3652.
3. Andrews A, et al. 1999. Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 40:2683-2689.
4. Bali E, et al. 2003. IL-10 in vivo gene expression in a cell-induced animal model of proliferative vitreoretinopathy. Int. J. Mol. Med. 12:305-310.
5. Ball SG, Shuttleworth CA, Kielty CM. 2007. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J. Cell Biol. 177:489-500.
6. Banerjee S, et al. 2007. Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders. Invest. Ophthalmol. Vis. Sci. 48: 2203-2207.
7. Baudouin C, et al. 1993. Growth factors in vitreous and subretinal fluid cells from patients with proliferative vitreoretinopathy. Ophthalmic Res. 25:52-59.
8. Bowen-Pope DF, Ross R. 1985. Methods for studying the platelet-derived growth factor receptor. Methods Enzymol. 109:69-100.
9. Burke CL, Stern DF. 1998. Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface. Mol. Cell. Biol. 18:5371-5379.
10. Reference deleted.
11. Campochiaro PA. 1997. Mechanisms in ophthalmic disease: pathogenic mechanisms in proliferative vitreoretinopathy. Arch. Ophthalmol. 115: 237-241.
12. Canataroglu H, et al. 2005. Interleukin (IL)-6, interleukin (IL)-8 levels and cellular composition of the vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretinopathy, and traumatic proliferative vitreoretinopathy. Ocul. Immunol. Inflamm. 13:375-381.
13. Charteris DG. 1998. Growth factors in proliferative vitreoretinopathy. Br. J. Ophthalmol. 82:106.
14. Cui JZ, et al. 2007. Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy. Eye 21:200-208.
15. Dieudonne SC, et al. 2007. Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy. Ophthalmic Res. 39:148-154.
16. El-Ghrably IA, Dua HS, Orr GM, Fischer D, Tighe PJ. 2001. Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. Br. J. Ophthalmol. 85:461-470.
17. Elner SG, et al. 1995. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr. Eye Res. 14:1045-1053.
18. Fredriksson L, Li H, Eriksson U. 2004. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev. 15: 197-204.
19. Gilbertson DG, et al. 2001. Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J. Biol. Chem. 276:27406-27414.
20. Glaser BM, Cardin A, Biscoe B. 1987. Proliferative vitreoretinopathy: the mechanism of development of vitreoretinal traction. Ophthalmology 94: 327-332.
21. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855-4878.
22. Grinnell F, Ho CH, Lin YC, Skuta G. 1999. Differences in the regulation of fibroblast contraction of floating versus stressed collagen matrices. J. Biol. Chem. 274:918-923.
23. Han D. 2008. Proliferative vitreoretinopathy, p 2315-2324. Elsevier Saunders, Philadelphia, PA.
24. Harada C, Mitamura Y, Harada T. 2006. The role of cytokines and trophic factors in epiretinal membranes: involvement of signal transduction in glial cells. Prog. Retin. Eye Res. 25:149-164.
25. Hart CE, et al. 1988. Two classes of PDGF receptor recognize different isoforms of PDGF. Science 240:1529-1531.
26. Himanen JP, Nikolov DB. 2003. Eph receptors and ephrins. Int. J. Biochem. Cell Biol. 35:130-134.
27. Himanen JP, Saha N, Nikolov DB. 2007. Cell-cell signaling via Eph receptors and ephrins. Curr. Opin. Cell Biol. 19:534-542.
28. Hinton DR, He S, Jin ML, Barron E, Ryan SJ. 2002. Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye 16: 422-428.
29. Ikuno Y, Kazlauskas A. 2002. An in vivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated plateletderived growth factor alpha receptor. Invest. Ophthalmol. Vis. Sci. 43: 2406-2411.
30. Ikuno Y, Kazlauskas A. 2002. TGFbeta1-dependent contraction of fibroblasts is mediated by the PDGFα receptor. Invest. Ophthalmol. Vis. Sci. 43:41-46.
31. Ikuno Y, Leong FL, Kazlauskas A. 2000. Attenuation of experimental proliferative vitreoretinopathy by inhibiting the platelet-derived growth factor receptor. Invest. Ophthalmol. Vis. Sci. 41:3107-3116.
32. Jackson JG, Post SM, Lozano G. 2011. Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. J. Pathol. 223:127-136.
33. Klinghoffer RA, Duckworth B, Valius M, Cantley L, Kazlauskas A. 1996. Platelet-derived growth factor-dependent activation of phosphatidylinositol 3-kinase is regulated by receptor binding of SH2-domain-containing proteins which influence Ras activity. Mol. Cell. Biol. 16:5905-5914.
34. Kon CH, Occleston NL, Aylward GW, Khaw PT. 1999. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest. Ophthalmol. Vis. Sci. 40:705-712.
35. La Heij EC, et al. 2002. Basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in vitreous fluid from eyes with retinal detachment complicated by proliferative vitreoretinopathy. Am. J. Ophthalmol. 134: 367-375.
36. Laqua H, Machemer R. 1975. Glial cell proliferation in retinal detachment (massive periretinal proliferation). Am. J. Ophthalmol. 80:602-618.
37. Lashkari K, Rahimi N, Kazlauskas A. 1999. Hepatocyte growth factor receptor in human RPE cells: implications in proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 40:149-156.
38. Lee IG, Chae SL, Kim JC. 2006. Involvement of circulating endothelial progenitor cells and vasculogenic factors in the pathogenesis of diabetic retinopathy. Eye 20:546-552.
39. Lei H, et al. 2007. A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 48: 2335-2342.
40. Lei H, Kazlauskas A. 2009. Growth factors outside of the platelet-derived growth factor (PDGF) family employ reactive oxygen species/Src family kinases to activate PDGF receptor alpha and thereby promote proliferation and survival of cells. J. Biol. Chem. 284:6329-6336.
41. Lei H, Rheaume MA, Kazlauskas A. 2010. Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy. Exp. Eye Res. 90: 376-381.
42. Lei H, Rheaume MA, Velez G, Mukai S, Kazlauskas A. 2011. Expression of PDGFRα is a determinant of the PVR potential of ARPE19 cells. Invest. Ophthalmol. Vis. Sci. 52:5016-5021.
43. Lei H, et al. 2010. N-Acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy. Am. J. Pathol. 177: 132-140.
44. Lei H, et al. 2009. Growth factors outside the PDGF family drive experimental PVR. Invest. Ophthalmol. Vis. Sci. 50:3394-3403.
45. Lei H, Velez G, Kazlauskas A. 2011. Pathological signaling via plateletderived growth factor receptor α involves chronic activation of Akt and suppression of p53. Mol. Cell. Biol. 31:1788-1799.
46. Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
47. Linggi B, Carpenter G. 2006. ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol. 16:649-656.
48. Mukherjee S, Guidry C. 2007. The insulin-like growth factor system modulates retinal pigment epithelial cell tractional force generation. Invest. Ophthalmol. Vis. Sci. 48:1892-1899.
49. Muller YA, Christinger HW, Keyt BA, de Vos AM. 1997. The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 Å resolution: multiple copy flexibility and receptor binding. Structure 5:1325-1338.
50. Muller YA, et al. 1997. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc. Natl. Acad. Sci. U. S. A. 94:7192-7197.
51. Oefner C, D'Arcy A, Winkler FK, Eggimann B, Hosang M. 1992. Crystal structure of human platelet-derived growth factor BB. EMBO J. 11:3921-3926.
52. Pastor JC. 1998. Proliferative vitreoretinopathy: an overview. Surv. Ophthalmol. 43:3-18.
53. Pennock S, Kazlauskas A. 2011. A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy. Am. J. Pathol. 179: 2931-2940.
54. Rahimi N, Kazlauskas A. 1999. A role for cadherin-5 in regulation of vascular endothelial growth factor receptor 2 activity in endothelial cells. Mol. Biol. Cell 10:3401-3407.
55. Raines EW, Ross R. 1985. Purification of human platelet-derived growth factor. Methods Enzymol. 109:749-773.
56. Reigstad LJ, Varhaug JE, Lillehaug JR. 2005. Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the plateletderived growth factors family. FEBS J. 272:5723-5741.
57. Robbins SG, et al. 1994. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest. Ophthalmol. Vis. Sci. 35:3649-3663.
58. Ryan SJ. 1993. Traction retinal detachment. XLIX. Edward Jackson Memorial Lecture. Am. J. Ophthalmol. 115:1-20.
59. Seifert RA, et al. 1989. Two different subunits associate to create isoformspecific platelet-derived growth factor receptors. J. Biol. Chem. 264:8771-8778.
60. Toledo F, Wahl GM. 2006. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6:909-923.
61. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. 1994. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269:26988-26995.
62. Zheng Y, et al. 2003. Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy. Jpn. J. Ophthalmol. 47:158-165.